ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / MNOV / financials
TENX (39) ZYBT (40) OSTX (42) RNXT (31) ⌘ Pro Terminal β†’

Medicinova Inc (MNOV) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.40 0.00% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.40

Medicinova Inc (MNOV) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (30/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE E β€’ RED ALERT Cap $68.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MNOV Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is MNOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Medicinova Inc (NASDAQ: MNOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.40 (0.00% 1D, market cap $68.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MNOV ranks #854 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does MNOV compare to TENX and ZYBT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNOV carries a Roarable E (30/100 RQD), trailing P/E of 5.7x, gross margin of β€”, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MNOV?
β–Ό

Per MNOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001226616), Medicinova Inc generated $409.7K in revenue, $12.0M in net income, and -$9.8M in free cash flow against $45.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.40 (-0.19%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (30/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (3)Whales (7)SEC (7)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.9% Base Target
$4 Bull$1 Base$1 Bear
πŸ“¬ FREE MNOV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for MNOV)Realized 20D OHLCV Swing Band: Β±10.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
πŸ” WHY MNOV SCORES 30/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+10/20 pts (33% of score)

FRED Regime Γ— Technicals: 7% of 52W Range β€’ RSI-14 at 38.4 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±10.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$1.52-6.6% Next Q
Q2 (-2Q)
35
Grade E$1.42-2.1% Next Q
Q3 (-1Q)
33
Grade E$1.39+0.7% Next Q
Current
30
Grade E$1.40-9.6% Hist 90D Ξ±
Trajectory: E (38) β†’ E (30)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a MNOV Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While MNOV currently carries a cautious 30/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.47) forces dealer call-delta covering toward $4.09.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNOVβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œMNOV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How MNOV Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.0MGross Profit $520.0K (52%)Cost of Sales $480.0KOp Profit $0 (0%)OpEx (R&D/SG&A) $520.0KNet Profit$12.0M (1199.8%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $1.0M
FY24
Rev $1.0M
FY25
Rev $409.7K
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$409.7K52%-80%$12.0M-$9.8M-45%
FY 2024$1.0M52%-1267.5%$11.1M-$10.6M-45%
FY 2023$1.0M52%-80%$8.6M-$7.4M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNOV)

  • βœ“Walkthrough of MNOV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
MNOV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.72%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-10-30O $1.42H $1.42L $1.38C $1.40VOL 29.7K
RES: $4.71SUP: $1.37SMA50: $1.79SMA200: $1.51
$4.09$3.31$2.53$1.76$0.98RES $4.71SUP $1.37$1.402026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNOV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ MNOV Butterfly Map β†’ + Track MNOV β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
-11.7%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MNOV today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for MNOV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MNOV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNOV)

Health Care Rank #854 of 1016 βš”οΈ TENX vs MNOV Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (MNOV vs. TENX, ZYBT, OSTX, RNXT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Medicinova Inc (MNOV) ranks #854 by composite RQD confidence (30/100, grade E) and #709 by equity capitalization ($68.9M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with MNOV at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MNOV ACTIVE
Medicinova Inc
E 30/100 5.7x β€” -35.0% 0.00% $68.9M Benchmark Subject
TENX
Tenax Therapeutics Inc.
D- 39/100 β€” β€” -35.0% -3.76% $69.6M /tenx-vs-mnov β†’
ZYBT
Zhengye Biotechnology Holding Limited (Class A)
D- 40/100 β€” 20.5% -22.3% -9.09% $67.8M /zybt-vs-mnov β†’
OSTX
OS Therapies Incorporated
D- 42/100 β€” β€” -35.0% -4.61% $67.6M /ostx-vs-mnov β†’
RNXT
RenovoRx Inc.
E 31/100 β€” 70.9% -35.0% -10.74% $67.2M /rnxt-vs-mnov β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001226616

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medicinova Inc (MNOV) reported GAAP revenue of $409.7K (N/A vs. FY2024 revenue of $0 , and -59.0% cumulative change since FY2023) , GAAP net income of $12.0M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (+7.8% YoY). On the balance sheet, MNOV closed FY2025 with $45.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $409.7K $12.0M -$9.8M -$9.8M $45.6M β€”
FY2024 (FY) 2024-12-31 $0 $11.1M -$10.6M -$10.6M $55.9M β€”
FY2023 (FY) 2023-12-31 $1.0M $8.6M -$7.4M -$7.4M β€” β€”

3. MNOV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Medicinova Inc (NASDAQ: MNOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.40 (0.00% 1D, market cap $68.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MNOV ranks #854 in composite RQD confidence.

How does MNOV compare to TENX and ZYBT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNOV carries a Roarable E (30/100 RQD), trailing P/E of 5.7x, gross margin of β€”, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MNOV?

Per MNOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001226616), Medicinova Inc generated $409.7K in revenue, $12.0M in net income, and -$9.8M in free cash flow against $45.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MNOV trading relative to its 50-day, 200-day, and 52-week technical levels?

MNOV last traded at $1.40 (0.00% on volume of 29,687 shares), positioning the stock -21.79% below its 50-day simple moving average ($1.79) and -7.28% below its 200-day simple moving average ($1.51). Across its 52-week range of $1.22 to $3.90, MNOV sits at the 6.7% percentile with a 14-day RSI of 38.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±10.5% ($1.25 to $1.55).

MNOV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

How profitable is Medicinova Inc (MNOV)?

In FY 2025 (10-K), MNOV converted $1.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: MNOV RQD Cockpit MNOV 12M Forecast MNOV Earnings & Move MNOV Dividends & DRIP MNOV Insiders & 13F MNOV Whale Options MNOV Profit Sankey MNOV News & Why
ROARABLE RATING BRIEF β€’ RQD 30/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

MNOV β€” Medicinova Inc: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline
As of: 2026-11-02T14:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Medicinova Inc (MNOV) carries a composite score of 30/100 (E β€” Roarable Strong Sell β€” Forensic Risk / Avoid) at a current price of $1.40 (0.00%). Fundamental cash generation scores 1/20 (ROIC -35.0%, FCF yield -14.24%), institutional 13F whale accumulation scores 7/20, insider conviction scores 5/20, macro regime alignment scores 10/20 (Beta 1.00), and forensic balance-sheet protection scores 7/20 (Altman Z-Score 0.20, Piotroski F-Score 3/9).

Investor Implication: At 5.7x trailing P/E and 5.3x forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (-60.0%) and free cash flow conversion relative to the 52-week range of $1.22 – $3.90.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MNOV is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin β€”), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

MNOV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Medicinova Inc (MNOV) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to MNOV Debate Forum (3) ↓
🟑 MARKET WIRE Yahoo β€’ 21d ago
MediciNova CEO Provides Shareholder Update

LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)

Read Full Source β†—
🟑 MARKET WIRE Benzinga β€’ 21d ago
MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance

To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MNOV Bull vs. Bear Conversation Board β€” What's Your Call at $1.40?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MNOV 🐻 67% BEARISH CONVICTION
1. Pick Your Side on MNOV:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.23 (-12.1%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is MNOV (E β€’ RQD 30/100) a Buy at $1.40?

Welcome to the MNOV (Medicinova Inc) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.09 (-22.1%)
Spot @ $1.40

Pump the brakes on MNOV β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MNOV, but look at what you are paying: 5.7x trailing P/E with tightening sector spreads. Unless Medicinova Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $1.61 (+15.0%)
Spot @ $1.40

MNOV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MNOV, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.40 (52-wk range $1.22 - $3.90), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%